JP2024528935A5 - - Google Patents

Info

Publication number
JP2024528935A5
JP2024528935A5 JP2024506163A JP2024506163A JP2024528935A5 JP 2024528935 A5 JP2024528935 A5 JP 2024528935A5 JP 2024506163 A JP2024506163 A JP 2024506163A JP 2024506163 A JP2024506163 A JP 2024506163A JP 2024528935 A5 JP2024528935 A5 JP 2024528935A5
Authority
JP
Japan
Prior art keywords
seq
nos
antigen
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024506163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074409 external-priority patent/WO2023015170A2/en
Publication of JP2024528935A publication Critical patent/JP2024528935A/ja
Publication of JP2024528935A5 publication Critical patent/JP2024528935A5/ja
Withdrawn legal-status Critical Current

Links

JP2024506163A 2021-08-02 2022-08-02 抗cd38抗体、抗cd3抗体、及び二重特異性抗体、並びにその使用 Withdrawn JP2024528935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163228195P 2021-08-02 2021-08-02
US63/228,195 2021-08-02
PCT/US2022/074409 WO2023015170A2 (en) 2021-08-02 2022-08-02 Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Publications (2)

Publication Number Publication Date
JP2024528935A JP2024528935A (ja) 2024-08-01
JP2024528935A5 true JP2024528935A5 (cg-RX-API-DMAC7.html) 2025-09-11

Family

ID=83049800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506163A Withdrawn JP2024528935A (ja) 2021-08-02 2022-08-02 抗cd38抗体、抗cd3抗体、及び二重特異性抗体、並びにその使用

Country Status (9)

Country Link
US (1) US20250277051A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380977A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024528935A (cg-RX-API-DMAC7.html)
KR (1) KR20240042009A (cg-RX-API-DMAC7.html)
CN (1) CN117751144A (cg-RX-API-DMAC7.html)
AU (1) AU2022323166A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226428A1 (cg-RX-API-DMAC7.html)
IL (1) IL310024A (cg-RX-API-DMAC7.html)
WO (1) WO2023015170A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
WO2025162453A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体前药及其应用
WO2025201242A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
WO2025201240A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
CN119236080A (zh) * 2024-09-29 2025-01-03 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) 一种医药组合物在制备用于治疗多发性硬化药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
PL3122781T3 (pl) * 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
EP3374397A2 (en) * 2015-11-10 2018-09-19 University Medical Center Hamburg - Eppendorf Antigen-binding polypeptides directed against cd38
CN111788225B (zh) * 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
WO2020087065A1 (en) * 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
CA3144961A1 (en) * 2019-07-01 2021-01-07 Sorrento Therapeutics, Inc. Heterodimeric antibodies that bind to cd38 and cd3

Similar Documents

Publication Publication Date Title
TWI924796B (zh) 抗cldn6抗體及其用途
US12630626B2 (en) Anti-CLDN18.2 antibody and uses thereof
JP2024544520A5 (cg-RX-API-DMAC7.html)
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
JP2019107018A5 (cg-RX-API-DMAC7.html)
AU2021353368B2 (en) Anti-cd3 antibody and uses thereof
JP2021514664A5 (cg-RX-API-DMAC7.html)
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2024531409A5 (cg-RX-API-DMAC7.html)
JP2023539501A5 (cg-RX-API-DMAC7.html)
JP2023546743A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
WO2019184549A1 (zh) 双特异性抗体及其应用
CN115335400A (zh) 结合整合素avb8的抗体及其用途
WO2023025187A1 (zh) 特异性结合cd47的抗体、其重组溶瘤病毒及其用途
WO2024001669A1 (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物
JP2024546939A5 (cg-RX-API-DMAC7.html)
CN117659194B (zh) 靶向egfr的纳米抗体、药物偶联物及其用途
CN103417965A (zh) 一种含有抗vegf抗体的药物组合物
CA3206472A1 (en) Anti-trpv6 monoclonal antibody and application thereof
CN116496398B (zh) 一种特异性结合CD44的v5外显子的抗体及其用途
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024131835A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof